Aktie A0M4GC KANGMEI PHARMACEUTICAL CO., LTD.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Kangmei Pharmaceutical Co., Ltd.

Aktien

A0M4GC

CNE0000017M1

600518

Schlusskurs Shanghai S.E.
Andere Börsenplätze
 00:00:00 07.06.2024 		% 5 Tage % 1. Jan.
1,88 CNY +1,08 % Intraday Chart für Kangmei Pharmaceutical Co., Ltd. +1,62 % +1,08 %
30.04. Kangmei Pharmaceutical verzeichnet Gewinn in Q1 MT
29.04. Kangmei Pharmaceutical Co., Ltd. meldet Ergebnis für das erste Quartal bis zum 31. März 2024 CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!
100% kostenlose Registrierung
Kangmei Pharmaceutical Logs Profit in Q1
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
Kangmei Pharmaceutical Returns to Profit in 2023; Shares Decline 4%
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Court Dismisses Winding-Up Petition Against Kangmei Pharma's Unit
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
China’s Securities Regulator Fines 37 Brokerages Since H1 2019
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
Former Kangmei Chairman Loses Appeal Against 12-Year Sentence
Kangmei Pharmaceutical Co., Ltd. announced that it has received CNY 6.5 billion in funding from Guangdong Shennong Enterprise Management Partnership (Limited Partnership), GF Securities Co., Ltd., Investment Arm, Wuhu Xintongrui Enterprise Management Center (Limited Partnership), Shenzhen Zhaoping Linghang Investment Center (Limited Partnership), China Resources Shenzhen International Investment Trust Co., Ltd.
Kangmei Pharmaceutical Co., Ltd. announced that it expects to receive CNY 6.5 billion in funding from Guangdong Shennong Enterprise Management Partnership (Limited Partnership), GF Securities Co., Ltd., Investment Arm, Wuhu Xintongrui Enterprise Management Center (Limited Partnership), Shenzhen Zhaoping Linghang Investment Center (Limited Partnership), China Resources Shenzhen International Investment Trust Co., Ltd.
Kangmei Fraud Case Decision Triggers Exodus of Independent Directors From Listed Firms
Kangmei to Get $1 Billion Government-Led Bailout
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A0M4GC Aktie
  4. Nachrichten Kangmei Pharmaceutical Co., Ltd.
  5. Andere Sprachen
-40 % Zeitlich begrenztes Angebot: Unsere Abonnements führen Sie zu den besten Investitionen von morgen.
PROFITIEREN SIE JETZT